Faron Lifted By US Immunotherapy Trial Approval

Plans For Breakthrough Status Application

 
• By Andrew McConaghie

After a major setback to its lead asset last year, Faron looks to novel immunotherapy

Stock_Market_Screen
The news has revived Faron's depressed share price

More from Anticancer

More from Therapy Areas